Improving cancer survival represents the most significant effect of precision medicine and personalized molecular and immunologic therapeutics. Cardiovascular health becomes henceforth a key determinant for the direction of overall outcomes after cancer. Comprehensive tissue diagnostic studies undoubtedly have been and continue to be at the core of the fight against cancer. Will a systemic approach integrating circulating blood-derived biomarkers, multimodality imaging technologies, strategic panomics, and real-time streams of digitized physiological data overcome the elusive cardiovascular tissue diagnosis in cardio-oncology? How can such a systemic approach be personalized for application in day-to-day clinical work, with diverse patient populations, cancer diagnoses, and therapies? To address such questions, this scientific statement approaches a broad definition of the biomarker concept. It summarizes the current literature on the utilization of a multitude of established cardiovascular biomarkers at the intersection with cancer. It identifies limitations and gaps of knowledge in the application of biomarkers to stratify the cardiovascular risk before cancer treatment, monitor cardiovascular health during cancer therapy, and detect latent cardiovascular damage in cancer survivors. Last, it highlights areas in biomarker discovery, validation, and clinical application for concerted efforts from funding agencies, scientists, and clinicians at the cardio-oncology nexus.

中文翻译：

---

癌症幸存者心血管生物标志物利用的未来前景：美国心脏协会的科学声明

提高癌症生存率代表了精准医疗和个性化分子和免疫疗法的最显着效果。心血管健康从此成为癌症后总体结果方向的关键决定因素。毫无疑问，综合组织诊断研究一直并将继续成为抗击癌症的核心。整合循环血液衍生生物标志物、多模态成像技术、战略性全景组学和数字化生理数据实时流的系统性方法能否克服心脏肿瘤学中难以捉摸的心血管组织诊断？如何将这种系统性方法个性化以应用于日常临床工作，包括不同的患者群体、癌症诊断和治疗方法？为了解决这些问题，这一科学声明接近了生物标志物概念的广义定义。它总结了当前关于在癌症交叉点使用大量已建立的心血管生物标志物的文献。它确定了应用生物标志物在癌症治疗前对心血管风险进行分层、在癌症治疗期间监测心血管健康以及检测癌症幸存者的潜在心血管损伤方面的局限性和知识差距。最后，它强调了生物标志物的发现、验证和临床应用领域，以供资助机构、科学家和临床医生在心脏肿瘤学关系中共同努力。它总结了当前关于在癌症交叉点使用大量已建立的心血管生物标志物的文献。它确定了应用生物标志物在癌症治疗前对心血管风险进行分层、在癌症治疗期间监测心血管健康以及检测癌症幸存者的潜在心血管损伤方面的局限性和知识差距。最后，它强调了生物标志物的发现、验证和临床应用领域，以供资助机构、科学家和临床医生在心脏肿瘤学关系中共同努力。它总结了当前关于在癌症交叉点使用大量已建立的心血管生物标志物的文献。它确定了应用生物标志物在癌症治疗前对心血管风险进行分层、在癌症治疗期间监测心血管健康以及检测癌症幸存者的潜在心血管损伤方面的局限性和知识差距。最后，它强调了生物标志物的发现、验证和临床应用领域，以供资助机构、科学家和临床医生在心脏肿瘤学关系中共同努力。